Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (791)	4/11/2006 6:37:58 AM
From: nigel bates	Read Replies (1) \| Respond to of 1022

Domantis also has a strong Australian link through Peptech, a Sydney-based biotech company, which has a 34 per cent shareholding and several research collaborations with it. "Ablynx is very much a European company and we shall keep our centre of gravity in Europe," says Dr Moses... Peptech is publically traded in Australia, so possible worth a look as a means of getting exposure. They have a decent licensing income from their TNF IP (following the usual legal battles), some very early stage clinical stuff, and a potentially quite profitable animal health business. The stock hasn't gone anywhere in the last couple of years - uk.finance.yahoo.com One to have a look at ?